Fingerprint
Dive into the research topics of 'Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT) (Radiation Oncology, (2021), 16, 1, (163), 10.1186/s13014-021-01888-1)'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically